Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEANIC-STROKE: Asundexian for prevention of ischemic stroke after non-cardioembolic ischemic stroke or high-risk TIA
2023-503793-20-00Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial in Noncardioembolic stroke (NCES), transient ischaemic attack (TIA) and atherosclerotic cerebrovascular disease comparing Asundexian with Placebo (2 arms). Primary endpoints: Time to first occurrence of ischemic stroke and Time to first occurrence of ISTH major bleeding. Started Sep 2023; status: completed.
02
Drugs
asundexian
03
Conditions
Noncardioembolic stroke (NCES)transient ischaemic attack (TIA)atherosclerotic cerebrovascular disease
Beyond the preview
Go deeper on 2023-503793-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503793-20-00.